Markerless motion capture for the clinical assessment of human movement

描述(由申请人提供)：这个项目的总体目标是生产和商业化一种用于生物力学和临床实践的无标记运动捕获系统。与传统使用的基于标记的系统不同，无标记系统将为生物力学和临床实践提供简单、经济、高效和准确的人体运动3D测量。这个第二阶段项目的具体重点是使在第二阶段验证的原型成为一个健壮的产品，并将其商业化，用于步态分析和运动医学应用。 与公共健康相关：该应用程序建议开发一种由无标记运动捕获系统组成的商业产品，该系统将改变实现人体运动的临床评估的方式。这笔赠款将使这项技术在研究和临床实践中完成开发和商业化。在第一阶段，Mixamo和斯坦福大学已经成功地合作实现了一个原型，并在临床上进行了验证。这两个机构拥有人体运动分析领域最尖端的研究人员作为他们的团队成员。动作捕捉是Mixamo公司的核心业务之一，斯坦福生物运动实验室是无标记技术的诞生地。Mixamo的创始首席执行官斯特凡诺·科拉扎一直在斯坦福大学生物移动实验室从事这项技术的早期阶段工作，他是目前拨款的私人侦探。在这一第二阶段的应用中，Mixamo率先为市场准备了一款产品，并将其商业化。这项技术已经走过了很长的路，已经准备好在临床步态分析和生物力学市场上产生革命性的影响。

DESCRIPTION (provided by applicant): The overall objective of this project is to productize and commercialize a markerless motion capture system for applications in biomechanical and clinical practice. The markerless system, as opposed to traditionally used marker based systems, would provide simple, cost effective, efficient and accurate 3D measurements of human movement for applications in biomechanical and clinical practice. The specific focus of this Phase II project is to make the prototype validated in Phase II a robust product and to commercialize it for gait analysis and sport medicine applications. PUBLIC HEALTH RELEVANCE: This application proposes the development of a commercial product consisting of a markerless motion capture system that will change the way clinical assessment of human motion is achieved. The grant will enable the completion of the developments and the commercialization of this technology in research and in clinical practices. In Phase I Mixamo and Stanford University have collaborated successfully in the realization of a prototype and its validation in a clinical setup. The two institutions have the most cutting edge researchers in the human motion analysis field as members of their teams. Motion capture is one of Mixamo, Inc's. core businesses and the Stanford Biomotion Lab is where the markerless technology was born. The founding CEO of Mixamo, Stefano Corazza, has been working on the early stagees of the technology at the Stanford Biomotion Lab and he is P.I. of the present grant. In this Phase II application Mixamo is taking the lead in making a product ready for the market and commercializing it. The technology has come a long way and is ready for a revolutionary impact in the market of clinical gait analysis and biomechanics.